Axon (AXON) CHO Elizabeth Coughlin Receives Award

What Happened

• Elizabeth Coughlin, Chief Human Officer of Axon (AXON), was granted 6,818 performance-based restricted stock units (XSUs) on August 16, 2026. The Form 4 reports the acquisition coded as "A" (award) at $0.00 per share (total reported value $0).
• The award relates to XSUs originally granted on December 22, 2023 under the Axon 2024 eXponential Stock Plan; the company’s Compensation Committee certified that the performance conditions for this fourth tranche were met on August 16, 2026.

Key Details

• Transaction date: 2026-08-16; Form 4 filed 2026-08-17 (filed promptly).
• Transaction type/code: Award/Grant (Code A); 6,818 shares; price reported $0.00.
• Vesting: Tranche will vest on December 1, 2026, subject to continued employment through that date.
• Post-vesting restriction: Shares deliverable after vesting are subject to a minimum holding period until the earlier of (i) December 31, 2030 or (ii) the date a subsequent tranche vests (excluding shares withheld/sold for taxes).
• Shares owned after the transaction: Not specified in this filing.
• Footnote: Grant stems from the Dec 22, 2023 XSU award; performance certification occurred 8/16/2026.

Context

• These XSUs are performance-based RSUs: they only convert to stock if performance and service conditions are met and after the stated vesting date, and they carry a further holding restriction after vesting. This is a compensation award rather than an open-market purchase or sale, so it signals that performance criteria were met but is not an immediate cash transaction or liquidity event.